A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Recruiting now Phase 3 NCT07318558
Run by Merck Sharp & Dohme LLC · for 18 and older · Women
What this study is about
Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.
Who can join (things the study team will check)
The main inclusion criteria include but are not limited to the following: * Has histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube carcinoma of certain histologies. * Has completed primary debulking surgery or interval debulking surgery. * Has completed first-line (1L) platinum-based chemotherapy, with a response of stable disease, partial response, complete response or no evidence of disease per protocol. * Has provided tumor tissue that is not previously irradiated. * If human immunodeficiency virus (HIV) infected, has well-controlled HIV on antiretroviral therapy. * Has undetectable hepatitis B virus (HBV) viral load and received HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive. * Has undetectable hepatitis C virus (HCV) viral load if has a history of HCV infection. The main exclusion criteria include but are not limited to the following: * Has nonepithelial cancers, low-grade serous tumors, low-grade endometrioid tumors, borderline tumors. mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor, and undifferentiated carcinoma. * Has known active central nervous system (CNS) metastases and/or carcin…
Where this trial is running
- Mount Sinai Cancer Center ( Site 0029), Miami Beach, Florida, United States
- Orlando Health Winnie Palmer Hospital for Women and Babies ( Site 0085), Orlando, Florida, United States
- Winship Cancer Institute of Emory University ( Site 0037), Atlanta, Georgia, United States
- Parkview Research Center at Parkview Regional Medical Center ( Site 0055), Fort Wayne, Indiana, United States
- Women's Cancer Care ( Site 0018), Covington, Louisiana, United States
- Nebraska Methodist Hospital ( Site 0004), Omaha, Nebraska, United States
- University Of Nebraska Medical Center ( Site 0035), Omaha, Nebraska, United States
- Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0007), Tulsa, Oklahoma, United States
- Women & Infants Hospital ( Site 0001), Providence, Rhode Island, United States
- West Cancer Center and Research Institute ( Site 0013), Germantown, Tennessee, United States
- University of Tennessee Medical Center ( Site 0087), Knoxville, Tennessee, United States
- Hospital Aleman ( Site 2903), Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
+ 106 more sites.
Who to contact
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07318558.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.